New Delhi, Feb 28 (PTI) Drug firm Zydus Cadila today said it has received final approval from US health regulator to market Dexmedetomidine Hydrochloride injection used for sedation of intubated and mechanically ventilated patients. Also Read - 'Another Phase of Greatest Witch Hunt', Says Donald Trump After US Senate Acquits Him in Historic Impeachment Trial

The approval from USFDA is to market Dexmedetomidine Hydrochloride injection 200 mcg (base)/ 2 ML and 100 mcg (base)/ ML single dose virals, Zydus Cadila said in a regulatory filing. Also Read - US Court Seeks Status Report On Visas To Family Members Of H1-B Holders

The injection will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad. Also Read - The Weeknd Performs Live At Super Bowl Halftime Show, Fans Share His Then-And-Now Photos

The drug is indicated for sedation of intubated and mechanically ventilated patients during treatment in an intensive care setting and for sedation of non-intubated patients prior to and/or during surgical and other procedures, the company said.

Shares of Cadila Healthcare, the company’s listed entity, were today trading 0.54 per cent down at Rs 404.75 apiece on BSE. PTI PRJ SBT

This is published unedited from the PTI feed.